Scholarlink

Purpose of Review <p>Chronic hepatitis B (HBV) infection remains a major global contributor to liver disease, yet current antiviral therapies infrequently achieve a functional cure. This review highlights emerging data on 2 novel agents that are designed to suppress viral antigen expression and potentially restore immune control of the infection.</p> Recent Findings <p>Imdusiran and bepirovirsen are 2 leading experimental therapies that target HBV RNA and have shown meaningful reductions in hepatitis B surface antigen and occasional instances of functional cure.</p> Summary <p> The emergence of RNA-targeted therapies marks a pivotal advancement in HBV treatment, shifting the focus beyond viral suppression to include immune restoration. A strong, coordinated immune response is needed, as evidenced by seroconversion patterns in treatment-responsive individuals. Moving forward, successful HBV cure strategies will likely involve combination regimes, pairing RNA-targeted agents with nucleos(t)ide analogues for viral suppression or immunomodulators like pegylated interferon-alfa-2a to effectively reestablish immune control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strategies to Achieve Functional Cure in HBV: Focus on siRNA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Eyyel Karthikeyan,
  • Robert G. Gish

摘要

Purpose of Review

Chronic hepatitis B (HBV) infection remains a major global contributor to liver disease, yet current antiviral therapies infrequently achieve a functional cure. This review highlights emerging data on 2 novel agents that are designed to suppress viral antigen expression and potentially restore immune control of the infection.

Recent Findings

Imdusiran and bepirovirsen are 2 leading experimental therapies that target HBV RNA and have shown meaningful reductions in hepatitis B surface antigen and occasional instances of functional cure.

Summary

The emergence of RNA-targeted therapies marks a pivotal advancement in HBV treatment, shifting the focus beyond viral suppression to include immune restoration. A strong, coordinated immune response is needed, as evidenced by seroconversion patterns in treatment-responsive individuals. Moving forward, successful HBV cure strategies will likely involve combination regimes, pairing RNA-targeted agents with nucleos(t)ide analogues for viral suppression or immunomodulators like pegylated interferon-alfa-2a to effectively reestablish immune control.